Tharimmune, Inc. Files 8-K with Financials
Ticker: CNTN · Form: 8-K · Filed: Sep 5, 2025 · CIK: 1861657
| Field | Detail |
|---|---|
| Company | Tharimmune, INC. (CNTN) |
| Form Type | 8-K |
| Filed Date | Sep 5, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $2,500,000, $1.7 million, $5.35 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-disclosure, financial-statements, exhibits
TL;DR
THARIMMUNE FILES 8-K WITH FINANCIALS AND EXHIBITS.
AI Summary
Tharimmune, Inc. filed an 8-K on September 5, 2025, reporting other events and financial statements. The company, formerly known as Hillstream BioPharma Inc. until May 11, 2021, and Tharimmune, Inc. until September 25, 2023, is incorporated in Delaware and headquartered in Red Bank, NJ. The filing includes financial statements and exhibits.
Why It Matters
This 8-K filing provides an update on Tharimmune, Inc.'s corporate activities and financial status, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not contain significant new information that would inherently increase risk.
Key Players & Entities
- Tharimmune, Inc. (company) — Registrant
- Hillstream BioPharma Inc. (company) — Former name
- September 5, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Red Bank, NJ (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report 'Other Events' and to include 'Financial Statements and Exhibits'.
When was Tharimmune, Inc. previously known by another name?
Tharimmune, Inc. was formerly known as Hillstream BioPharma Inc. until May 11, 2021.
What is the exact address of Tharimmune, Inc.'s principal executive offices?
The address of Tharimmune, Inc.'s principal executive offices is 34 Shrewsbury Avenue, Suite 1C, Red Bank, NJ 07701.
What is the Commission File Number for Tharimmune, Inc.?
The Commission File Number for Tharimmune, Inc. is 001-41210.
What is the fiscal year end for Tharimmune, Inc.?
The fiscal year end for Tharimmune, Inc. is December 31 (1231).
Filing Stats: 582 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2025-09-04 21:11:05
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value THAR The Nasdaq Stock Mar
- $2,500,000 — ompany's stockholder equity be at least $2,500,000. On May 15, 2025, the Company submitted
- $1.7 million — nts for gross proceeds of approximately $1.7 million. In addition, on August 27, 2025, the C
- $5.35 million — ts) for gross proceeds of approximately $5.35 million. As a result of the transactions descr
Filing Documents
- form8-k.htm (8-K) — 38KB
- ex99-1.htm (EX-99.1) — 14KB
- 0001641172-25-026620.txt ( ) — 217KB
- thar-20250905.xsd (EX-101.SCH) — 3KB
- thar-20250905_lab.xml (EX-101.LAB) — 33KB
- thar-20250905_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 5, 2025 Tharimmune, Inc. /s/ Sireesh Appajosyula Sireesh Appajosyula Chief Executive Officer -3-